Roche's GIP/GLP-1 dual receptor agonist enicepatide has successfully reached two major endpoints in its phase II clinical trial involving obesity and type 2 diabetes.

Zhitongcaijing · 2d ago
Roche's GIP/GLP-1 dual receptor agonist enicepatide has successfully reached two major endpoints in its phase II clinical trial involving obesity and type 2 diabetes.